Archive by category | Blood stem cells

Hematopoiesis, no hedgehog needed

While covering a couple papers just out in Cell Stem Cell, reporter Simone Alves uncovered an interesting conversation about how the genetic constructs used to explore a protein’s role can affect results: This will be on the main site next week, but I thought I’d post it here for now.  Read more

Around the web: some stem cell synopses

Why do I seem to be working harder and harder, but covering less and less? The vast majority of my readers, I’m sure, found the answer long before I did. In the eighteen months since Nature Reports Stem Cells has gone live, stem-cell happening have increased appreciably, inexorably, exhaustingly.  Read more

Cancer stem cells: controversies and misconceptions

Nature recently published a paper by Sean Morrison and others finding that melanoma stem cells are not rare and that standard assays to identify tumorigenic cells fail to detect a large portion of them. This prompted two letters describing an earlier study by David Taussig and others which found that the antibodies used to detect the leukemogenic cells first identified by John Dick changed their behaviour. Another letter pointed out the role that the extracellular matrix plays in shielding transplanted cells from the immune response, and suggested that this could provide insight in developing immune-based therapies to cancer.  Read more

Blood-forming and esophageal stem cells: find, see, manipulate

Blood-forming stem cells have recently garnered some attention. Genzyme’s drug to boost circulating stem cells in patients with blood cancers won FDA approval on Monday. Here is Genzyme’s description of its small molecule chemokine receptor antagonist. Also, two research teams from Stanford have found ways to make artificial versions of the microenvironments where blood forms (See below), and a third team from Germany and Switzerland describes away to track individual blood-forming stem cells .  Read more

Umbilical Cord Blood Companies in Asia

This week, announcements of deals to bank and use umbilical cord blood in China, India, Vietnam and South Korea point to an industry that is both promising and prone to overpromising. Companies trying to attract self-paying patients often conflate established therapies with highly experimental and unproven procedures.  Read more